Randomized study evaluating testosterone recovery using shortversus long-acting luteinizing hormone releasing hormone agonists

Journal of the Canadian Urological Association

Volumn 5, Issue 3, 2011, Pages 173-179

  Pai, Howard Huaihan ^a,b   Pickles, Tom ^a,b   Keyes, Mira ^a,b   Jones, Stuart ^c   Mcdonald, Rachel E ^d   Lesperance, Mary ^e   Berthelet, Eric ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958134868     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.10102     Document Type: Article

References (25)

1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-6.
2. D'Amico A, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
3. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
4. Kintzel PE, Chase SL, Schultz LM, et al. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008;28:1511-22.
5. Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008;180:1432-7
6. D'Amico AV, Renshaw AA, Loffredo B, et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007;110:1723-8.
7. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-44
8. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005;173:1567-71.
9. Murthy V, Norman AR, Shahidi M, et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int 2006;97:476-9.
10. Pickles T, Agranovich A, Berthelet E, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002;94:362-7.
11. Nejat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000;164:1891-4.
12. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685-8.
13. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94.
14. Morris WJ, Keyes M, Palma D, et al. Evaluation of Dosimetric Parameters and Disease Response After (125)Iodine Transperineal Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2009;7:1432-8.
15. Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-ofthe- science review. Int J Impot Res 2002;14:226-44.
16. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: NY: Wiley; 2002.
17. Gleave ME, Goldenberg SL, Sullivan LD, et al. Recovery of testosterone levels after neoadjuvant hormone therapy - comparison of 3 vs 8 months treatment prior to radical prostatectomy. J Urol 2000;163(Suppl):292.
18. Petit JH, Gluck C, Kiger WS, 3rd, et al. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol 2008;26:372-7.
19. Amies CJ, Mameghan H, Rose A, et al. Testicular doses in definitive radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:839-46.
20. Tomic R, Bergman B, Damber JE, et al. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin. J Urol 1983;130:287-9.
21. Daniell HW, Clark JC, Pereira SE, et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer 2001;91:1889-95.
22. Pickles T, Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 2002;167:2448-52.
23. Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:85-9.
24. Giberti C, Barreca T, Martorana G, et al. Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue. Eur Urol 1988;15:125-7.
25. Linde R, Doelle GC, Alexander N, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med 1981;305:663-7.